La Jolla Pharmaceutical Company (LJPC): Price and Financial Metrics
GET POWR RATINGS... FREE!
LJPC Stock Price Chart Interactive Chart >
LJPC Price/Volume Stats
|Current price||$6.22||52-week high||$6.24|
|Prev. close||$6.22||52-week low||$3.07|
|Day high||$6.24||Avg. volume||158,476|
|50-day MA||$5.06||Dividend yield||N/A|
|200-day MA||$4.45||Market Cap||155.11M|
La Jolla Pharmaceutical Company (LJPC) Company Bio
La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. The company was founded in 1989 and is based in San Diego, California.
Most Popular Stories View All
LJPC Latest News Stream
|Loading, please wait...|
LJPC Latest Social Stream
View Full LJPC Social Stream
Latest LJPC News From Around the Web
Below are the latest news stories about LA JOLLA PHARMACEUTICAL CO that investors may wish to consider to help them evaluate LJPC as an investment opportunity.
Come, thou long-expected M&A. On Monday, Vertex Pharmaceuticals Inc. and Innoviva Inc. both announced that they were making acquisitions. Vertex (Nasdaq: VRTX) is set to buy ViaCyte, a cell therapy startup specializing in diabetes, for $320 million cash, while Innoviva will pay about $149 million for infectious diseases firm La Jolla Pharmaceutical Company (Nasdaq: LJPC).
With the help of nearly $400 million in royalties from a well-known drug targeting asthma and COPD, the company wrapped up one acquisition and launched another.
Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional cash proceeds received in connection with the divestiture of a non-core asset. The deal consideration of $6.23 per share in cash has an implied enterprise value of approximately $149 million. The FDA approved La Jolla's lead
BURLINGAME, Calif. & WALTHAM, Mass., July 11, 2022--Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress
WALTHAM, Mass., May 16, 2022--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighted corporate progress.
LJPC Price Returns
Continue Researching LJPCWant to do more research on La Jolla Pharmaceutical Co's stock and its price? Try the links below:
La Jolla Pharmaceutical Co (LJPC) Stock Price | Nasdaq
La Jolla Pharmaceutical Co (LJPC) Stock Quote, History and News - Yahoo Finance
La Jolla Pharmaceutical Co (LJPC) Stock Price and Basic Information | MarketWatch